Achaogen takes in $5.6M to fight bacterial infections
Pharmaceutical company Achaogen received a $5.6 million grant from the U.K.-based Wellcome Trust as part of its Seeding Drug Discovery Initiative. The money will go toward phase one clinical trials of the San Francisco company’s lead drug candidates, aimed at treating bacterial infections that are already resistent to multiple antibiotics.
It last raised funds in 2006, bringing in $26 million in second-round funding from Venrock, Versant Ventures, Domain Associates and Arch Venture Partners.
Next Story: Fark.com goes mainstream with Jeopardy appearance
Previous Story: Gene Security Network strings together $6M for in-vitro tech
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.